Skip to main content
OpenTrials
Completed

NCT Number: NCT00491283

QuickVue Influenza A+B Clinical Field Trial

A comparative study of different swab types used for collection of specimens for rapid inluenza testing

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sydney Airport Medical Centre

Mascot, New South Wales, 2020, Australia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects must have:

  • Fever (>38°C) (at time of visit or within the previous 48 hrs by history) and at least two of the following symptoms:
  • Chills/sweats
  • Cough
  • Dyspnea (labored, difficult breathing)
  • Fatigue
  • Headache
  • Myalgia (deep muscle aches)
  • Nasal congestion
  • Runny nose
  • Sore throat

Exclusion criteria

  • Patients who are undergoing treatment with antivirals, now or within the last 7 days cannot be included in this study.

Treatment and study plan

Swab Specimen Collection (QuickVue)

Device

Primary outcomes

  1. Sensitivity and Specificity

    Time frame: five months

Secondary outcomes

  1. Sensitivity and Specificity

    Time frame: Positive and Negative Predictive Values

Sponsors and collaborators

Lead sponsor

Quidel Corporation

Industry

Registry information

Official study title

Comparison of Swab Types for Specimen Collection

Important dates

Study start
2006
Primary completion
2006
Study completion
2006
First posted
Jun 26, 2007
Registry last updated
Jan 28, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.